News

It understands complex drug interactions and scores the strength of medical evidence, such as weighing a validated clinical trial more than a case study, Jeff Tangney, co-founder and CEO of Doximity, told investors during the company's fiscal first-quarter earnings call Thursday, according to a transcript of the call. The acquisition of Pathway Medical marks a strategic move to bolster its AI capabilities, and the deal should help the combined entity "compete with novel providers like OpenEvidence," wrote Ryan Daniels, an analyst with William Blair, in an analyst note following Doximity's earnings call. "We like the deal and believe that the combination of Doximity GPT, the new AI-scribe tool, and Pathway's AI-based clinical tools (answering provider questions at the point of care) are helping Doximity become a clear leader in the AI space," Daniels wrote. "At present, we believe the company will continue to provide the full AI toolset for free to providers but expect that over the longer term (within the next one to two years) it could move to sell enterprise-grade solutions to health systems (similar to the path it took with Doximity Dialer)."